跳至主要内容
临床试验/CTRI/2010/091/000495
CTRI/2010/091/000495已完成4 期

A gamma scintigraphy study to determine the lung deposition of inhaled aerosolized radiolabeled budesonide/formoterol(200/6mcg)in patients with COPD and Asthma (Phase IV study)

Glenmark Pharmaceuticals Ltd.,Glenmark House,HDO-Corporate Building,Wing-A, B.D. Sawant Marg, Chakala,Off Western Express Highway,Andheri (E) Mumbai 400099.0 个研究点目标入组 10 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • (i) Outpatients, men ≥ 40 years
  • (ii) COPD diagnosed as a forced expiratory volume in 1 second (FEV1) of no more than 65% of predicted, a ratio of FEV1 to forced vital capacity (FVC) of no more than 0.70 and who are current or former smokers (at least 10 pack
  • (iii) Patients with stable mild to moderate persistent asthma; asthma diagnosed as improvement ≥12% reversibility in FEV1 or FVC following administration of an inhaled β2-agonist; baseline forced expiratory volume in one second 60% ≤(FEV1)≤ 90% of predicted value; Stability was ascertained if the patient remained in the same severity class (mild, moderate) and had no acute exacerbations by investigator judgment during the past 14 days
  • (iv) Ability to master pMDI inhalation technique in dummy experiments
  • (v) Written informed consent by patients
  • (vi) Patients willing to follow up.

排除标准

  • For COPD Patients
  • (i) A history and/or current clinical diagnosis of asthma and atopic diseases such as allergic rhinitis
  • (ii) Patients who have experienced COPD exacerbation requiring at least one of the following treatments, hospitalization and/or a course of systemic steroid within 4 weeks prior to the study start.
  • (iii) Patients with significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator, or any other relevant cardiovascular disorder as judged by the investigator
  • Patients with congenital heart diseases, lung cancer, thoracic restrictive disorders or any other coexisting diseases influencing 3-yr survival.
  • For asthma patients
  • (i) Hospitalization due to asthma during the previous 3 months
  • (ii) Respiratory tract infection requiring treatment with antibiotics in the previous 4 weeks;
  • (iii) Oral or systemic corticosteroids in the previous 4weeks;
  • (2) Patients unable to inhale pMDI properly and with consistency
  • (3)Patients with known hypersensitivity to budesonide or formoterol, Technetium 99 m to compounds structurally related to the study drugs or to any other component included
  • (4)Heavy smokers or patients with underlying respiratory problems interfering with vital capacity or giving rise to PFT abnormality or inconsistency
  • (5)Patients with osteoporosis or any condition predisposing to low bone density
  • (6)Patients receive an investigational drug within 30 days prior to admission to the study
  • (7)Patients with out of normal range values in any of the following laboratory blood tests: complete blood count, blood glucose, ionogram, AST, ALT, total bilirrubin, total proteins, urea, creatinine, total cholesterol and triglycerides and urine potassium levels.
  • (8)Any other condition that in the opinion of the investigator does not justify the patient?s participation in the study

研究者

发起方
Glenmark Pharmaceuticals Ltd.,Glenmark House,HDO-Corporate Building,Wing-A, B.D. Sawant Marg, Chakala,Off Western Express Highway,Andheri (E) Mumbai 400099.

相似试验